The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC.
 
Zofia Piotrowska
Consulting or Advisory Role - Abbvie; ARIAD/Takeda; AstraZeneca; Boehringer Ingelheim; Guardant Health; Novartis; Superdimension
Research Funding - ARIAD/Takeda (Inst); Guardant Health (Inst); Novartis (Inst)
 
Stephen V. Liu
Consulting or Advisory Role - ARIAD; AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech; Ignyta; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Bayer; Clovis Oncology; Corvus Pharmaceuticals; Esanex; Genentech/Roche; Ignyta; Lycera; MedImmune; Merck; OncoMed; Pfizer; Threshold Pharmaceuticals
 
Alona Muzikansky
No Relationships to Disclose
 
Nicolas Marcoux
Honoraria - Bristol-Myers Squibb
 
Mandeep Banwait
No Relationships to Disclose
 
Sara Stevens
No Relationships to Disclose
 
Kelly Goodwin
No Relationships to Disclose
 
Tracey E Lafferty
No Relationships to Disclose
 
Jennifer Ackil
No Relationships to Disclose
 
Elizabeth A Krueger
No Relationships to Disclose
 
Rebecca Suk Heist
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Abbvie (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Debiopharm Group (Inst); Exelixis (Inst); Incyte (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Peregrine Pharmaceuticals (Inst); Roche (Inst)
 
Jessica Jiyeong Lin
Honoraria - Chugai Pharma
Consulting or Advisory Role - Boehringer Ingelheim
 
Justin F. Gainor
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech; Loxo; Takeda; Theravance
Research Funding - Adaptimmune (Inst); ARIAD; AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Affymetrix
 
Aaron N. Hata
Research Funding - Amgen; Novartis; Relay Therapeutics
 
Alice Tsang Shaw
Honoraria - Foundation medicine; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ARIAD; Blueprint Medicines; Daiichi Sankyo; EMD Serono; Genentech; Ignyta; KSQ Therapeutics; Loxo; Natera; Novartis; Pfizer; Roche; Taiho Pharmaceutical; Takeda
Research Funding - Novartis; Pfizer; Roche/Genentech
 
Lecia V. Sequist
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Genentech (Inst); Guardant Health (Inst); Incyte (Inst); Johnson & Johnson (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst)